Choose a Topic
- All Topics
- ASH 2017
- AML
- MDS
- Lymphomas and CLL
- Older Patient HCT
- Sickle Cell Disease
- Post-Transplant
- GVHD
- Patient Eligibility
- CIBMTR Publications
- Cord Blood
- Pediatric HCT
- ALL
- CML
- Multiple Myeloma
- Neuroblastoma
- Non-Malignant Disorders
- HLA Matching
- Preparative Regimens
- BMT CTN Publications
- Unrelated Donor HCT
- ASH 2018
- ASH 2020
Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
A safe and effective shared care approach after allogeneic HCT could be a new standard of care
December 2022
Abel GA, et al. – Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition showed a shared care approach after allogeneic hematopoietic cell transplantation did not compromise non-relapse mortality and may be associated with improved quality of life.
Lack of collaborative relationships between physician teams associated with HCT care decisions
April 2022
Steffens K, et al. – Research shared at the 2022 Tandem Meetings of the ASTCT and CIBMTR presents survey outcomes from community hematology/oncology physicians regarding the strength of their relationships with local transplant centers. Community physicians with a lower self-rated relationship strength with transplant centers reported less support for early HCT treatment behaviors and lower confidence in managing patients post-transplant.
Zeiser R, et al. Blood – The latest research in cellular therapies, antibody-based treatments, and tyrosine kinase inhibitor (TKI)-based approaches to enhance GVL effects are outlined in articles published in a special edition of Blood.